Earnings Summary

Axsome Therapeutics, Inc.’s revenue jumped 81.27% since last year same period to $104.76Mn in the Q3 2024. On a quarterly growth basis, Axsome Therapeutics, Inc. has generated 20.19% jump in its revenue since last 3-months.

Axsome Therapeutics, Inc.’s net profit fell -3.86% since last year same period to $-64.6Mn in the Q3 2024. On a quarterly growth basis, Axsome Therapeutics, Inc. has generated 18.58% jump in its net profits since last 3-months.

Axsome Therapeutics, Inc.’s net profit margin jumped 42.7% since last year same period to -61.67% in the Q3 2024. On a quarterly growth basis, Axsome Therapeutics, Inc. has generated 32.26% jump in its net profit margins since last 3-months.

Axsome Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -1.21.

Axsome Therapeutics, Inc.’s earning per share (EPS) fell -1.66% since last year same period to -1.34 in the Q3 2024. This indicates that the Axsome Therapeutics, Inc. has generated -1.66% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Axsome Therapeutics, Inc.’s return on assets (ROA) stands at -0.26.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Axsome Therapeutics, Inc.’s return on equity (ROE) stands at -1.72.